



FOR IMMEDIATE RELEASE

Agile Therapeutics CFO Scott Coiante Named Finalist for New Jersey Technology Council's 2012 CFO of the Year

– New Jersey Technology Council CFO Awards Recognize Accomplishments of New Jersey Financial Executives –

PRINCETON, N.J. – June 08, 2012 – Agile Therapeutics, a pharmaceutical company focused on developing and commercializing more convenient women's contraceptive products, today announced that its Chief Financial Officer, Scott Coiante, has been named a finalist for CFO of the Year at the New Jersey Technology Council's 2012 CFO Awards, which recognize the accomplishments of financial executives from New Jersey and the surrounding region's diverse technology companies. Agile's President and CEO Al Altomari and Mr. Coiante attended the awards breakfast in Monroe Township, New Jersey on June 8, 2012.

The CFO of the Year Award is presented to a Chief Financial Officer of a technology firm for outstanding contributions to the company's performance and accomplishments from January 2011 through the present. Criteria for the award include being a confidant to the company's CEO, adept at raising capital and case management, and an outstanding team builder, as well as heightening a company's public image, playing an integral role in deal negotiation, and implementing a major project.

Mr. Coiante was nominated as CFO of the Year based on Agile's development of AG200-15, a low-dose, once-weekly combination hormonal contraceptive patch that recently completed Phase III trials and for which Agile has submitted a new drug application (NDA) to the Food and Drug Administration (FDA). The nomination recognizes Mr. Coiante's success in raising capital and building substantive strategic alliances as the company moves its product through development.

"We are thrilled that Scott has received this recognition from the New Jersey Technology Council. Being named a finalist for 2012 CFO of the Year by this prestigious organization is a testament to Scott's commitment to Agile's mission of developing more convenient contraceptive options for women," said Mr. Altomari. "Scott has played an instrumental role in building business relationships and raising the funds that we need to bring AG200-15 to market and we are proud to see his hard work recognized."

About Agile Therapeutics

Agile Therapeutics is a pharmaceutical development company specializing in Women's Healthcare products, with an initial focus on providing women with more options and more convenient methods of hormonal contraception. The company's lead product, AG200-15, is a once-weekly contraceptive patch that has been submitted to the FDA for approval. In addition, Agile is also developing a low dose,

progestin-only contraceptive patch, AG890 (formerly AG900). Both AG200-15 and AG890 incorporate proprietary transdermal delivery technology, Skinfusion[®], developed by Agile, consisting of an active and peripheral adhesive system that allows stable drug delivery and dependable adhesion over seven days. For more information, please visit <http://www.agiletherapeutics.com>.

About the New Jersey Technology Council

The NJTC, now in its 15th year of supporting technological companies, has succeeded in making New Jersey the “go-to state” for growth-oriented innovators. The NJTC offers its 1,000+ member companies access to networking, financing resources, expertise and more. A private, non-for-profit membership organization, the NJTC fosters and grows a vibrant entrepreneurial spirit and nurtures a community where great ideas take flight. For more information, please visit <http://www.njtc.org/>.

Contact:

Chantal Beaudry or Karen Famighetti for Agile Therapeutics
cbeaudry@lazarpartners.com
kfamighetti@lazarpartners.com
212-867-1762